首页> 外文期刊>Circulation research: a journal of the American Heart Association >Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy])
【24h】

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy])

机译:心力衰竭患者静脉内输液的安全性和功效心力衰竭患者1/2随机对照试验(RIMECARD试验[静脉内输注脐带脐带间充质干细胞的随机临床试验])

获取原文
获取原文并翻译 | 示例
           

摘要

Rationale: Umbilical cord-derived mesenchymal stem cells (UC-MSC) are easily accessible and expanded in vitro, possess distinct properties, and improve myocardial remodeling and function in experimental models of cardiovascular disease. Although bone marrow-derived mesenchymal stem cells have been previously assessed for their therapeutic potential in individuals with heart failure and reduced ejection fraction, no clinical trial has evaluated intravenous infusion of UC-MSCs in these patients.
机译:理由:脐带衍生的间充质干细胞(UC-MSC)易于进入并在体外膨胀,具有不同的特性,并改善心血管疾病实验模型中的心肌重塑和功能。 尽管先前已经评估了骨髓衍生的间充质干细胞,但在心力衰竭和降低喷射部分中的个体中进行治疗潜力,但在这些患者中没有评估静脉注射UC-MSC的临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号